Patents Represented by Attorney, Agent or Law Firm Li Su
-
Patent number: 7799825Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.Type: GrantFiled: February 14, 2007Date of Patent: September 21, 2010Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpAInventors: Federica Ferrigno, Philip Jones, Ester Muraglia, Jesus Maria Ontoria Ontoria, Rita Scarpelli, Carsten Schultz-Fademrecht
-
Patent number: 7795304Abstract: The invention relates to hydroxamic acid derivatives having carbamate linkage with the structural formula that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous systems (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.Type: GrantFiled: August 22, 2005Date of Patent: September 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Sandro Belvedere, Christopher Laurence Hamblett, Thomas A. Miller, David J. Witter, Jiaming Yan
-
Patent number: 7772238Abstract: The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: GrantFiled: April 14, 2006Date of Patent: August 10, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Jed Lee Hubbs, Sam Kattar, Joey Methot, Thomas Miller, Phieng Siliphaivanh, Matthew Stanton, Kevin Wilson, David J. Witter
-
Patent number: 7560546Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: GrantFiled: August 5, 2003Date of Patent: July 14, 2009Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, Douglas C. Beshore, Jeffrey M. Bergman, Craig W. Lindsley
-
Patent number: 7538231Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: GrantFiled: July 20, 2004Date of Patent: May 26, 2009Assignee: Merck & Co, Inc.Inventor: Annette S. Kim
-
Patent number: 7507858Abstract: This invention relates to iminodiacetic acid and diamine hydroxamic acid derivatives, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.Type: GrantFiled: July 15, 2005Date of Patent: March 24, 2009Assignee: Merck & Co., Inc.Inventors: Sandro Belvedere, Thomas A. Miller, David J. Witter
-
Patent number: 7504429Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: GrantFiled: July 20, 2004Date of Patent: March 17, 2009Assignee: Merck & Co., Inc.Inventors: Annette S. Kim, Xufang Zhang
-
Patent number: 7501435Abstract: The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: April 24, 2007Date of Patent: March 10, 2009Assignee: Merck & Co., Inc.Inventors: Kenneth L. Arrington, Edward J. Brnardic, Vadim Y. Dudkin, Mark E. Fraley, Shaei Y. Huang, Cheng Wang
-
Patent number: 7485649Abstract: The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: January 5, 2006Date of Patent: February 3, 2009Assignee: Merck & Co., Inc.Inventors: Edward J. Brnardic, Mark E. Fraley, Robert M. Garbaccio
-
Patent number: 7371754Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: GrantFiled: April 8, 2003Date of Patent: May 13, 2008Assignee: Merck & Co., Inc.Inventor: B. Wesley Trotter
-
Patent number: 7348431Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: GrantFiled: April 8, 2003Date of Patent: March 25, 2008Assignee: Merck & Co., Inc.Inventor: Annette Kim
-
Patent number: 6806085Abstract: Recombinant DNA molecules are described which contain a DNA sequence encoding a protein with the biological activity of a 2-deoxyglucose-6-phosphate (2-DOG-6-P) phosphatase and being under the control of regulatory sequences of a promoter active in plants and transcription-termination and/or poyladenylation signals. Also, vectors and hosts are described which contain the recombinant DNA molecules according to the invention. Furthermore, processes for producing transformed plant cells and plants using the described recombinant DNA molecules and vectors are provided. The invention also describes transgenic plants, their harvest products and propagation material as well as plant cells and tissues containing the recombinant DNA molecules or vectors according to the invention or having been produced by the process according to the invention.Type: GrantFiled: April 25, 2000Date of Patent: October 19, 2004Assignee: IPK GaterslebenInventors: Uwe Sonnewald, Marcus Ebneth
-
Patent number: 6790434Abstract: The invention relates to cosmetic compositions for topical application for counteracting UV radiation induced skin damage comprising as active substances a first component which comprises inactivated bacteria selected from the group consisting of the genus Bifidobacterium, Actinomycetaceae, Propionimycetaceae, Lactobacillaceae and Coryneform bacteria and a second component which comprises an extract of plant extracellular matrix. Preferably, the plant extracellular matrix is selected from the group consisting of glycoproteins, carbohydrate polymers and arabinogalactan proteins. Processes for using the cosmetic compositions are also described.Type: GrantFiled: November 5, 2001Date of Patent: September 14, 2004Assignee: Chemisches Laboratorium Dr. Kurt Richter GmbHInventors: Stefan Borchert, Rolf-Dieter Petersen
-
Patent number: 6692965Abstract: The invention is directed to reliable and efficient detection of mRNAs as well as other RNAs in living cells and its use to identify and, if desired, separate cells based on their desired characteristics. Such methods greatly simplify and reduce the time necessary to carry out previously-known procedures, and offers new approaches as well, such as selecting cells that generate a particular protein or antisense oligonucleotide, generating cell lines that express multiple proteins, generating cell lines with knock-out of one or more protein, and others.Type: GrantFiled: November 22, 2000Date of Patent: February 17, 2004Assignee: Chromocell CorporationInventors: Kambiz Shekdar, Gunter Blobel
-
Patent number: 6348315Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.Type: GrantFiled: October 22, 1999Date of Patent: February 19, 2002Assignee: University of Zürich, Assignee for Josef HanesInventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus
-
Patent number: 6255561Abstract: Nucleic acid molecules are described, which encode debranching enzymes from maize, as well as transgenic plant cells and plants in which an amylopectin with modified properties is synthesized due to the expression of a debranching enzyme from maize or due to the inhibition of such an endogeneous debranching enzyme activity.Type: GrantFiled: September 4, 1998Date of Patent: July 3, 2001Assignee: PlantTec Biotechnologie GmbHInventors: Jens Kossman, Lothar Willmitzer, Michael Emmermann
-
Patent number: 6255563Abstract: Nucleic acid molecules are described, which encode debranching enzymes from potato, as well as transgenic plant cells and plants in which an amylopectin with modified properties is synthesized due to the expression of a debranching enzyme from potato or due to the inhibition of such an endogeneous debranching enzyme activity.Type: GrantFiled: November 5, 1998Date of Patent: July 3, 2001Assignee: PlantTec Biotechnologie GmbHInventors: Michael Emmermann, Jens Kossmann
-
Patent number: 6211436Abstract: Nucleic acid molecules encoding enzymes which participate in the starch synthesis in plants are described. These enzymes are a novel isotype of starch synthase. Furthermore, the invention relates to vectors and host cells which were transformed with the described nucleic acid molecules, in particular to transformed plant cells and to plants which may be regenerated therefrom and which exhibit an increased or reduced activity of the described proteins.Type: GrantFiled: July 15, 1998Date of Patent: April 3, 2001Assignee: Planttec Biotechnologie GmbHInventors: Jens Kossmann, Claus Frohberg